文献速递肿瘤 PET/CT放射性药物与辐射防护核素与放射性配体治疗

68Ga-NODAGA-RGDyK首次人体辐射剂量学研究

First in-human radiation dosimetry of 68Ga-NODAGA-RGDyK.
PubMed 文献 · EJNMMI Res · 2017-05-18

在5例连续入组的男性患者中,于注射200 MBq 68Ga-NODAGA-RGDyK后10、60、120分钟行全身TOF PET/CT,验证定量方法并计算器官剂量。吸收剂量最高的器官为膀胱、肾脏和脉络丛;按ICRP60/ICRP103,30分钟排尿周期有效剂量分别为15.7和16.5 μSv/MBq,1小时排尿周期分别为19.3和19.8 μSv/MBq;注射200 MBq时有效剂量为3.86/3.92 mSv。

要点

  • 5例男性患者注射200 MBq 68Ga-NODAGA-RGDyK后行全身TOF PET/CT显像。
  • 膀胱、肾脏和脉络丛吸收剂量最高,女性剂量由男性数据外推平均高17%。
  • 按ICRP60/ICRP103,200 MBq注射有效剂量为3.86/3.92 mSv。

核心结论

  • 按ICRP60/ICRP103建议,注射200 MBq 68Ga-NODAGA-RGDyK在人体产生的有效剂量为3.86/3.92 mSv。
  • 作者认为,未来治疗应用应特别关注肾脏递送剂量,并可能也需关注脉络丛。

研究设计与样本

  • 本研究为首次人体辐射剂量学研究,纳入临床颈动脉粥样硬化斑块显像方案中连续入组的5例男性患者。
  • 5例患者于注射200 MBq 68Ga-NODAGA-RGDyK后10、60和120分钟行全身TOF PET/CT扫描。
  • 68Ga活度浓度定量先经体模研究验证,时间-活度曲线由脑、甲状腺、肺、心脏、肝、脾、胃、肾、红骨髓、胰腺、小肠、结肠、膀胱和全身手动勾画感兴趣区获得,并输入OLINDA/EXM。
  • 脉络丛另行剂量学分析;女性剂量由男性数据外推。
  • 有效剂量按ICRP60和ICRP103估算,分别假设30分钟和1小时排尿周期。

主要发现

  • 吸收剂量最高的体部区域为膀胱、肾脏和脉络丛。
  • 30分钟排尿周期下,按ICRP60和ICRP103估算的有效剂量分别为15.7和16.5 μSv/MBq。
  • 1小时排尿周期外推下,按ICRP60和ICRP103估算的有效剂量分别为19.3和19.8 μSv/MBq。
  • 女性剂量外推结果平均较男性患者器官吸收剂量高17%。
  • 文中将本研究结果与既往小鼠剂量学及采用其他RGD类放射性药物的既往人体研究进行了比较。

临床怎么用

  • 作者认为,未来治疗应用应特别关注肾脏递送剂量,并可能也需关注脉络丛。

局限性

  • 女性剂量学由男性数据外推获得。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Integrin-targeting radiopharmaceuticals have potential broad applications, spanning from cancer theranostics to cardiovascular diseases. We have previously reported preclinical dosimetry results of 68Ga-NODAGA-RGDyK in mice. This study presents the first human dosimetry of 68Ga-NODAGA-RGDyK in the five consecutive patients included in a clinical imaging protocol of carotid atherosclerotic plaques. Five male patients underwent whole-body time-of-flight (TOF) PET/CT scans 10, 60 and 120 min after tracer injection (200 MBq). Quantification of 68Ga activity concentration was first validated by a phantom study. To be used as input in OLINDA/EXM, time-activity curves were derived from manually drawn regions of interest over the following organs: brain, thyroid, lungs, heart, liver, spleen, stomach, kidneys, red marrow, pancreas, small intestine, colon, urinary bladder and whole body. A separate dosimetric analysis was performed for the choroid plexuses. Female dosimetry was extrapolated from male data. Effective doses (EDs) were estimated according to both ICRP60 and ICRP103 assuming 30-min and 1-h voiding cycles. RESULTS: The body regions receiving the highest dose were urinary bladder, kidneys and choroid plexuses. For a 30-min voiding cycle, the EDs were 15.7 and 16.5 μSv/MBq according to ICRP60 and ICRP103, respectively. The extrapolation to female dosimetry resulted in organ absorbed doses 17% higher than those of male patients, on average. The 1-h voiding cycle extrapolation resulted in EDs of 19.3 and 19.8 μSv/MBq according to ICRP60 and ICRP103, respectively. A comparison is made with previous mouse dosimetry and with other human studies employing different RGD-based radiopharmaceuticals. CONCLUSIONS: According to ICRP60/ICRP103 recommendations, an injection of 200 MBq 68Ga-NODAGA-RGDyK leads to an ED in man of 3.86/3.92 mSv. For future therapeutic applications, specific attention should be directed to delivered dose to kidneys and potentially also to the choroid plexuses. TRIAL REGISTRATION: Clinical trial.gov, NCT01608516.

来源:EJNMMI Res,查看原文。版权归原作者所有。

引用

  1. Gnesin S, Mitsakis P, Cicone F, et al. First in-human radiation dosimetry of 68Ga-NODAGA-RGDyK. EJNMMI Res. 2017. PMID: 28523582. doi:10.1186/s13550-017-0288-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。